Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Nanomix Corp NNMX

Nanomix Corporation is engaged in development of mobile point-of-care diagnostics. The Company operates through its Nanomix eLab System platform and assays that provide quantitative information for use in settings where time is critical to clinical decision-making and improved patient care. The platform is designed to provide rapid test results in a handheld device at the first point of patient... see more

GREY:NNMX - Post Discussion

Nanomix Corp > Boston Therapeutics, Inc. (BTHE) Announces Three Management
View:
Post by MissionIR on Dec 10, 2013 5:30pm

Boston Therapeutics, Inc. (BTHE) Announces Three Management

Boston Therapeutics, Inc. (BTHE) Announces Three Management Appointments

Boston Therapeutics, an innovator of drugs that target diabetes using complex carbohydrate chemistry, today announced the appointment of three management positions within its ranks. Effective immediately, Edward Shea will serve as Vice President Business Development, Tina M. Gagnon will serve as Consulting Director of Finance, and Yael T. Bobruff, Ph.D. will serve as Clinical Affairs Manager, respectively.

David Platt, Ph.D., Chief Executive Officer, Boston Therapeutics, said, “As Boston Therapeutics enters the next phase of its growth, it is imperative that we attract top talent to help us advance and commercialize our drug development programs. Ed Shea and Tina Gagnon’s business and finance backgrounds, and Dr. Bobruff’s expertise in biology and research significantly strengthen our management team. I am pleased they have decided to join our company, and I look forward to working with them in the months and years ahead.”

Mr. Shea boasts of 25 years of experience in commercial development, marketing, and sales. Of that, 15 years of his experience includes business development, marketing, and sales leadership positions with GlaxoSmithKline and Salix Pharmaceuticals, as well as business development capacities with two startup biopharmaceutical companies, ViroPharma and Critical Therapeutics. Mr. Shea most recently worked with ViroPharma, Inc. as Sr. Eastern Area Sales Director. He holds a B.S. in Business/Marketing and an M.B.A. from Salve Regina University in Newport, RI.

Ms. Gagnon brings over 20 years of experience in finance. Most recently, she worked as Corporate Controller at Micronetics, Inc., at which she oversaw a staff responsible for accounts receivable, accounts payable, inventory management, and other activities. Beforehand, she served in the following capacities: Controller at Amherst Technologies, LLC; Assistant Controller of Fruit of the Loom’s Sports & Licensing Division; and Senior Corporate Auditor at Standex International Corp. Ms. Gagnon holds a B.S. in Accountancy from Bentley College.

Most recently, Dr. Bobruff was a postdoctoral researcher in the Department of Systems Biology at Harvard University Medical School in Boston. There, she investigated in depth the genetic processes and mechanisms contributing to the evolution of host-pathogen interactions. Dr. Bobruff holds a B.Sc. in Biology from the Hebrew University of Jerusalem, a M.Sc. in Civil and Environmental Engineering, and a Ph.D. in Biological Science from Stanford University.

For more information, visit www.bostonti.com

Please read full disclaimers at https://disclaimer.missionir.com

Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities